Histotype
Bladder
| Parameter | Information |
|---|---|
| Strain | NSG |
| Implant Type | Cells |
| Implant Location | SC, Axilla (High) |
| Time to Staging | 14 days |
| Time to Evaluation Size (days) | 25.5 days |
| Td | 3.4 days |
The above parameters are from one study. For further information on this cell line and other parameters, including different strains, vendors, implant type and location and/or standards of care, please contact us.
Tumor Line
Mouse
Ref #
9199
Spotlight on MB 49
Learn more about this cell line in our scientific spotlights:
"Bladder cancer is one of the most frequent cancers of the urinary tract, accounting for about 80,000 new cases and 18,000 deaths in the United States in 2018, according to the National Cancer Society. Typically, patients with bladder cancer have limited surgical or treatment options. Traditional chemotherapeutics are ineffective, and surgery is often used to diagnose bladder cancer and to determine whether the cancer has spread into (invaded) the muscle layer of the bladder wall. When bladder cancer is invasive, all or part of the bladder may need to be removed, leaving the patient with long term adverse effects. In an effort to meet the need for advances in bladder cancer treatment, in 2018 the FDA accelerated the approvals for two checkpoint inhibitors, Keytruda and Tecentriq . . . . "